FDA strengthens Trasylol warning

Source | Associated Press

WASHINGTON - The government strengthened warnings on a drug commonly used to lessen blood loss during heart bypass surgery, saying yesterday that doctors should reserve Trasylol for higher-risk patients.

The Food and Drug Administration began re-evaluating the safety of Trasylol, also called aprotinin, last January after studies raised the possibility of kidney failure, heart attacks and strokes after its use.

Yesterday, the FDA strengthened the drug’s label to:

• Specify that Trasylol be given only to patients at increased risk of blood loss during the surgery.

• Warn that Trasylol increases the risk of kidney damage.

• Suggest ways to lower patients’ risk for a life-threatening allergic reaction, and treat them if one occurs.

The FDA still is probing the drug’s potential cardiovascular risks, and left open the possibility of further warnings.

Do I Have A Trasylol Lawsuit?

If you or a loved one have recently undergone heart surgery and subsequently developed kidney or renal failure and are now undergoing dialysis treatments, you should contact us immediately by using the form at the bottom of this page, or by dialing Toll Free (866) 588-0600.

You may be entitled to compensation by filing a Trasylol lawsuit and we can help.